SCHEMBL16184787

SCHEMBL16184787

CNC(=O)C1CN(c2nc(-c3cccnc3)nc3c(OC)cc(-c4cc(F)ccc4F)cc23)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ NTRK1 P04629 1/20 0.38
▸ MAP4K1 Q92918 1/20 0.38
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38
▸ TUBA4A P68366 1/20 0.38
▸ TUBB4B P68371 1/20 0.38
▸ TUBB3 Q13509 1/20 0.38
▸ TUBB2A Q13885 1/20 0.38
▸ TUBB8 Q3ZCM7 1/20 0.38
▸ TUBA3E Q6PEY2 1/20 0.38
▸ TUBA1A Q71U36 1/20 0.38
▸ TUBA1C Q9BQE3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184773 0.94 MAPT (0.41) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184704 0.92 CYP11B1 (0.43) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184785 0.91 MAPT (0.48) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184738 0.91 MAPT (0.42) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184720 0.90 MAPT (0.40) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184805 0.90 MAPT (0.41) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184752 0.89 MAPT (0.41) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184822 0.89 MAPT (0.42) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL14474741 0.86 MAPT (0.41) MAPTLMNAKDM4ESMN1; SMN2CYP11B1
SCHEMBL16184769 0.85 MAPT (0.48) MAPTLMNAKDM4ESMN1; SMN2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885LMNA 4832/4885KDM4E 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback